Syquant Capital Sas Invests $3.85 Million in Oculis Holding AG $OCS

Key Points

• Syquant Capital Sas opened a new position in Oculis (NASDAQ:OCS), buying 192,722 shares worth about $3.85 million, which equals roughly 0.5% of Syquant’s portfolio and about 0.37% ownership of Oculis.
• Oculis reported quarterly EPS of ($0.51) (missing the ($0.43) estimate) but posted revenue of $0.50M (above the $0.14M consensus); the company remains unprofitable with a market cap near $1.45 billion and very negative profitability metrics.
• Analyst sentiment is mixed but skewed positive: seven Buy vs one Sell rating, a MarketBeat consensus target of $43.86, and recent price-target raises from firms like Needham and Stifel while some outlets retained or cut to Sell.

Syquant Capital Sas purchased a new position in Oculis Holding AG (NASDAQ:OCS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 192,722 shares of the company's stock, valued at approximately $3,849,000. Oculis accounts for 0.5% of Syquant Capital Sas' investment portfolio, making the stock its 18th largest position. Syquant Capital Sas owned approximately 0.37% of Oculis as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Aventura Private Wealth LLC acquired a new stake in Oculis during the fourth quarter worth about $80,000. Bosun Asset Management LLC acquired a new position in shares of Oculis in the 2nd quarter valued at approximately $378,000. Marshall Wace LLP bought a new stake in shares of Oculis during the 2nd quarter worth approximately $393,000. Geode Capital Management LLC lifted its holdings in shares of Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company's stock worth $571,000 after acquiring an additional 6,384 shares during the period. Finally, Bank of America Corp DE boosted its position in shares of Oculis by 2.2% during the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company's stock worth $786,000 after acquiring an additional 878 shares in the last quarter. Institutional investors own 22.30% of the company's stock.

Oculis Price Performance

OCS stock opened at $24.99 on Friday. Oculis Holding AG has a 1 year low of $14.00 and a 1 year high of $30.68. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.96 and a quick ratio of 5.96. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of -11.01 and a beta of 0.29. The company has a 50 day simple moving average of $27.44 and a 200 day simple moving average of $22.42.

Oculis (NASDAQ:OCS - Get Free Report) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.08). The company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.14 million. Oculis had a negative return on equity of 62.12% and a negative net margin of 8,173.41%. Research analysts anticipate that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on OCS. Needham & Company LLC lifted their price objective on shares of Oculis from $36.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, March 4th. Stifel Nicolaus raised their target price on Oculis from $40.00 to $50.00 and gave the company a "buy" rating in a report on Wednesday, March 4th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Oculis in a research note on Thursday, January 22nd. Wall Street Zen cut Oculis from a "hold" rating to a "sell" rating in a report on Saturday, March 7th. Finally, Lifesci Capital began coverage on Oculis in a research report on Wednesday, December 3rd. They set an "outperform" rating and a $55.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Oculis presently has an average rating of "Moderate Buy" and a consensus target price of $43.86.

Oculis Company Profile

Oculis SA NASDAQ: OCS is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.

Want to see what other hedge funds are holding OCS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oculis Holding AG (NASDAQ:OCS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.